Strategy of diagnosis and treatment for ultrafiltration failure of peritoneal dialysis

doi:10.3877/cma.j.issn.2095-3216.2016.03.001

Abstract

Abstract:

Ultrafiltration failure is a common complication and an important cause of peritoneal dialysis failure. Ultrafiltration failure is defined as that the net ultrafiltration volume is less than 400 ml after a 4-hour dwell with 4.25% dextrose dialysis solution. According to its pathophysiological mechanisms, the ultrafiltration failure has been divided into 4 types: type 1 ultrafiltration failure is caused by increase of effective peritoneal surface area; type 2 ultrafiltration failure is caused by decrease of osmotic conductance to glucose; type 3 ultrafiltration failure is caused by decrease of effective peritoneal surface area; and type 4 ultrafiltration failure is caused by absorbance of a lot of water through the peritoneal lymphatic system or local tissue gap. Beneficial methods to prevent and treat ultrafiltration failure include rational use of high glucose dialysate, effective prevention and treatment of peritoneal dialysis-related peritonitis, protection of residual renal function, appropriate use of biocompatible dialysates, and application of drugs to improve peritoneal damage and fibrosis.

Key words: Ultrafiltration failure, Peritoneal dialysis, Diagnosis, Treatment

Zhaohui Ni, Haijiao Jin. Strategy of diagnosis and treatment for ultrafiltration failure of peritoneal dialysis[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2016, 05(03): 97-100.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2016.03.001

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2016/V05/I03/97

References 22

[1]	Mujais S,Story K. Peritoneal dialysis in the US: evaluation of outcomes in contemporary cohorts[J]. Kidney Int, 2006, 103(70): 21-26.
[2]	Mujais S,Nolph K,Gokal R, et al. Evaluation and management of ultrafiltration problems in peritoneal dialysis[J]. Perit Dial Int, 2000, 20(Suppl 4): S5-S21.
[3]	Flessner MF. The transport barrier in intraperitoneal therapy[J]. Am J Physiol Renal Physiol, 2005, 288(3): F433-F442.
[4]	Teitelbaum I. Ultrafiltration failure in peritoneal dialysis: a pathophysiologic approach[J]. Blood Purif, 2015, 39(1-3): 70-73.
[5]	严豪,方炜,李振元, 等. 可溶性酪氨酸激酶2融合蛋白对尿毒症腹膜透析大鼠腹膜形态和功能的影响[J]. 中华肾脏病杂志, 2010, 26(7): 525-529.
[6]	Goffin E,Combet S,Jamar F, et al. Expression of aquaporin-1 in a long-term peritoneal dialysis patient with impaired transcellular water transport[J]. Am J Kidney Dis, 1999, 33(2): 383-388.
[7]	Aroeira LS,Aguilera A,Sánchez-Tomero JA, et al. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions[J]. J Am Soc Nephrol, 2007, 18(7): 2004-2013.
[8]	Kinashi H,Ito Y,Mizuno M, et al. TGF-β1 promotes lymphangiogenesis during peritoneal fibrosis[J]. J Am Soc Nephrol, 2013, 24(10): 1627-1642.
[9]	De Alvaro F,Castro MJ,Dapena F, et al. Peritoneal resting is beneficial in peritoneal hyperpermeability and ultrafiltration failure[J]. Adv Perit Dial, 1993, 9: 56.
[10]	Kolesnyk I,Noordzij M,Dekker FW, et al. A positive effect of AⅡ inhibitors on peritoneal membrane function in long-term PD patients[J]. Nephrol Dial Transplant, 2009, 24(1): 272-277.
[11]	La Milia V,Di Filippo S,Crepaldi M, et al. Mini-peritoneal equilibration test: a simple and fast method to assess free water and small solute transport across the peritoneal membrane[J]. Kidney Int, 2005, 68(2): 840-846.
[12]	Stoenoiu MS,Ni J,Verkaeren C, et al. Corticosteroids induce expression of aquaporin-1 and increase transcellular water transport in rat peritoneum[J]. J Am Soc Nephrol, 2003, 14(3): 555-565.
[13]	De Arteaga J,Ledesma F,Garay G, et al. High-dose steroid treatment increases free water transport in peritoneal dialysis patients[J]. Nephrol Dial Transplant, 2011, 26(12): 4142-4145.
[14]	Yool AJ,Morelle J,Cnops Y, et al. AqF026 is a pharmacologic agonist of the water channel aquaporin-1[J]. J Am Soc Nephrol, 2013, 24(7): 1045-1052.
[15]	Kawanishi H,Kawaguchi Y,Fukui H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study[J]. Am J Kidney Dis, 2004, 44(4): 729-737.
[16]	Vizzardi V,Sandrini M,Zecchini S, et al. Encapsulating peritoneal sclerosis in an Italian center: thirty year experience[J]. J Nephrol, 2016, 29(2): 259-267.
[17]	Hirahara I,Inoue M,Okuda K, et al. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis-a multicentre study in Japan[J]. Nephrol Dial Transpl, 2007, 22(2): 560-567.
[18]	Balasubramaniam G,Brown EA,Davenport A, et al. The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis[J]. Nephrol Dial Transpl, 2009, 24(8): 3209-3215.
[19]	Korte MR,Fieren MW,Sampimon DE, et al. Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study[J]. Nephrol Dial Transpl, 2011, 26(2): 691-697.
[20]	Hirahara I,Kusano E,Morishita Y, et al. Matrix metalloproteinase-2 as a superior biomarker for peritoneal deterioration in peritoneal dialysis[J]. World J Nephrol, 2016, 5(2): 204-212.
[21]	Dohi K. Surgical techniques for prevention of recurrence after total enterolysis in encapsulating peritoneal sclerosis[J]. Adv Perit Dial, 2008, 24: 51-55.
[22]	Baranowska-Daca E,Torneli J,Popovich RP, et al. Use of bethanechol chloride to increase available ultrafiltration in CAPD[J]. Adv Perit Dial, 1995, 11: 69-72.

Please choose a citation manager

Content to export